Onesource Specialty Pharma Stock Screener | Share Price & Fundamental Analysis
ONESOURCE
Pharmaceuticals
Screen Onesource Specialty Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1798.10
▲
1.40 (0.08%)
Share Price BSE
₹1798.45
▲
2.95 (0.16%)
Market Cap
₹20,484.38 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
3.51
EPS (TTM)
₹-1.63
Dividend Yield
-
Debt to Equity
0.21
52W High
₹2197.80
52W Low
₹1238.20
Operating Margin
43.00%
Profit Margin
23.08%
Revenue (TTM)
₹429.00
EBITDA
₹185.00
Net Income
₹99.00
Total Assets
₹7,550.00
Total Equity
₹5,881.00
Onesource Specialty Pharma Share Price History - Stock Screener Chart
Screen ONESOURCE historical share price movements with interactive charts. Analyze price trends and patterns.
Onesource Specialty Pharma Company Profile - Fundamental Screener
Screen Onesource Specialty Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ONESOURCE shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE013P01021
Onesource Specialty Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen ONESOURCE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Total Assets | 7,550 | 1,309 | 2,009 | 2,442 | 1,258 |
| Current Assets | 1,086 | 176 | 228 | 511 | 99 |
| Fixed Assets | 6,118 | 863 | 1,361 | 1,231 | 633 |
| Liabilities | |||||
| Total Liabilities | 7,550 | 1,309 | 2,009 | 2,442 | 1,258 |
| Current Liabilities | 556 | 282 | 358 | 621 | 321 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||
| Total Equity | 5,881 | 396 | 786 | 1,013 | 776 |
| Share Capital | 11 | 4 | 4 | 3 | 2 |
| Reserves & Surplus | 5,869 | 392 | 781 | 1,009 | 775 |
Screen ONESOURCE income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 429 | 333 | 379 | 76 | 296 | 338 | 399 | 10 | 34 | 88 |
| Expenses | 244 | 242 | 269 | 76 | 233 | 263 | 351 | 80 | 105 | 173 |
| EBITDA | 185 | 91 | 110 | 0 | 64 | 76 | 48 | -70 | -71 | -85 |
| Operating Profit % | 43.00% | 26.00% | 28.00% | -4.00% | 20.00% | 21.00% | 11.00% | -800.00% | -210.00% | -207.00% |
| Depreciation | 69 | 68 | 70 | 20 | 68 | 68 | 69 | 19 | 18 | 20 |
| Interest | 33 | 28 | 34 | 21 | 42 | 45 | 46 | 18 | 25 | 26 |
| Profit Before Tax | 83 | -4 | 6 | -40 | -47 | -38 | -67 | -107 | -114 | -130 |
| Tax | -16 | -4 | -5 | 0 | -41 | 5 | 2 | 0 | 0 | 0 |
| Net Profit | 99 | 0 | 11 | -40 | -6 | -42 | -69 | -107 | -114 | -130 |
| EPS | 8.61 | -0.02 | 0.92 | -9.67 | -0.51 | -10.13 | -6.31 | 0.00 | -27.37 | -31.32 |
Onesource Specialty Pharma Cash Flow Screener - Liquidity Fundamentals
Screen ONESOURCE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March |
|---|---|---|---|---|---|
| Operating Activities | -68 | -107 | -163 | -416 | -118 |
| Investing Activities | -201 | 511 | -68 | -692 | -207 |
| Financing Activities | 412 | -391 | 118 | 1,162 | 381 |
| Net Cash Flow | 143 | 13 | -112 | 55 | 56 |
Screen ONESOURCE shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Dec |
|---|---|---|---|---|
| Promoter Holding | 34.25% | 29.79% | 29.77% | 37.77% |
| FII Holding | 18.54% | 18.69% | 19.39% | 17.44% |
| DII Holding | 18.04% | 18.10% | 18.49% | 12.56% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 12.50% | 13.25% | 12.42% | 13.05% |
| Other Holding | 16.67% | 20.17% | 19.93% | 19.18% |
| Shareholder Count | 82,712 | 87,760 | 87,416 | 98,425 |
Onesource Specialty Pharma Dividend Screener - Share Yield Analysis
Screen ONESOURCE dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Onesource Specialty Pharma Index Membership - Market Screener Classification
Screen ONESOURCE by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Onesource Specialty Pharma Market Events Screener - Corporate Actions
Screen ONESOURCE market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -1.03% | ||
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -1.91% |
| 2025-08-04 | 2025-08-04 | Quarterly Result Announcement | NA | -7.38% |
| 2025-05-05 | 2025-05-05 | Quarterly Result Announcement | NA | -0.05% |
| 2025-01-29 | 2025-01-29 | Quarterly Result Announcement | NA | - |
| 2024-02-14 | 2024-02-14 | Change Of Name | NA | - |
Onesource Specialty Pharma Competitors Screener - Peer Comparison
Screen ONESOURCE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Onesource Specialty Pharma Company Announcements - News Screener
Screen ONESOURCE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-06 | Intimation Of The Press Release Of Credit Rating Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015 | View |
| 2025-12-30 | Closure of Trading Window | View |
| 2025-12-29 | Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2025-12-19 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | View |
| 2025-12-11 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-12-09 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-18 | Update On Non-Participation Of The Representatives Of The Company In The Jefferies Conference | View |
| 2025-11-13 | General Updates | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-12 | Investor Presentation | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-11 | Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-11-11 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 11/11/2025 To Approve The Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-05 | Board Meeting Intimation for Approving The Financial Results For The Quarter And Half Year Ended September 30 2025. | View |
| 2025-09-26 | Investor Presentation | View |
| 2025-09-26 | Announcement under Regulation 30 (LODR)-Scheme of Arrangement | View |